Regulatory B Cells—Immunopathological and Prognostic Potential in Humans

Abstract

The aim of the following review is to shed light on the putative role of regulatory B cells (Bregs) in various human diseases and highlight their potential prognostic and therapeutic relevance in humans. Regulatory B cells are a heterogeneous group of B lymphocytes capable of suppressing inflammatory immune reactions. In this way, Bregs contribute to the maintenance of tolerance and immune homeostasis by limiting ongoing immune reactions temporally and spatially. Bregs play an important role in attenuating pathological inflammatory reactions that can be associated with transplant rejection, graft-versus-host disease, autoimmune diseases and allergies but also with infectious, neoplastic and metabolic diseases. Early studies of Bregs identified IL-10 as an important functional molecule, so the IL-10-secreting murine B10 cell is still considered a prototype Breg, and IL-10 has long been central to the search for human Breg equivalents. However, over the past two decades, other molecules that may contribute to the immunosuppressive function of Bregs have been discovered, some of which are only present in human Bregs. This expanded arsenal includes several anti-inflammatory cytokines, such as IL-35 and TGF-β, but also enzymes such as CD39/CD73, granzyme B and IDO as well as cell surface proteins including PD-L1, CD1d and CD25. In summary, the present review illustrates in a concise and comprehensive manner that although human Bregs share common functional immunosuppressive features leading to a prominent role in various human immunpathologies, they are composed of a pool of different B cell types with rather heterogeneous phenotypic and transcriptional properties.

Therapeutic Avenues to Modulate B-Cell Function in Patients With Cardiovascular Disease

“…67,68 Initially, Bregs were identified by their ability to secrete the immunosuppressive cytokine IL-10, but more recently, there is growing evidence of other cytokines, enzymes, and surface receptors produced or expressed by this heterogenous group of cells including IL-35, TGF-β (transforming growth factor-β), CD39, CD73, PD-L1 (programmed death-ligand 1), CD1d, and CD25. 69,70 The most studied subset of Bregs remains the IL-10producing subset. 70 IL-10 mediates its suppressive effect via pathways involving T cells and macrophages.…”